Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-05-31
2005-05-31
Swartz, Rodney P (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C435S007320, C435S069100
Reexamination Certificate
active
06899880
ABSTRACT:
The present invention features the use of PorB polypeptide as a therapeutic agent. In specific embodiment the invention features a chlamydial vaccine based on a PorB polypeptide, as well as methods for induction of a protective immune response against infection byChlamydiaandChlamydiophila. The invention further features methods for identifying agents that affect PorB function such as in transport of α-ketoglutarate and which are effective as anti-chlamydial chemotherapeutic agents.
REFERENCES:
patent: 4267170 (1981-05-01), Seawell
patent: 4271146 (1981-06-01), Seawell
patent: 5242686 (1993-09-01), Chu et al.
patent: 5656271 (1997-08-01), MacDonald et al.
patent: 5716793 (1998-02-01), MacDonald et al.
patent: 5725863 (1998-03-01), Daniels et al.
patent: 5770714 (1998-06-01), Agabian et al.
patent: 5821055 (1998-10-01), Agabian et al.
patent: 5840297 (1998-11-01), MacDonald et al.
patent: 5972350 (1999-10-01), Atherton et al.
patent: 6166177 (2000-12-01), Probst et al.
patent: WO 94/06827 (1994-03-01), None
patent: WO 96/31236 (1996-10-01), None
patent: WO 97/41889 (1997-11-01), None
patent: WO 98/02546 (1998-01-01), None
patent: WO 98/10789 (1998-03-01), None
patent: WO 98/58953 (1998-12-01), None
patent: WO 99/10005 (1999-03-01), None
patent: WO 99/28475 (1999-06-01), None
patent: WO 99/28475 (1999-06-01), None
Marshal, E. “ Gene Therapy's Growing Pains” Science, vol. 269, pp. 1050-1055, Aug. 25, 1995..*
Seq ID No 2 ( PorB ) search report.*
Allen, et al. “A single peptide from the major outer membrane protein of chlamydia trachomatis elicits T cell help for the production of antibodies to protective determinants”, The Journal of Immunology vol. 147(2): 674-679 (1991).
Bavoil, et al. “Role of disulfide bonding in outer membrane structure and permeability in chlamydia trachomatis”, Infection and Immunity vol. 44(2): 479- 485 (1984).
Berman, et al. “Recommendations for the prevention and management of chlamydia trachomatis infections”, The Morbidity and Mortality Weekly Report vol. 42(RR-12): 1-102 (1993).
Caldwell, et al. “Purification and partial characterization of the major outer membrane protein of chlamydia trachomatis”, Infection and Immunity vol. 31(3): 1161-1176 (1981).
Everett, et al. “Architecture of the cell envelope of chlamydia psittaci 6BC”, Journal of Bacteriology vol. 177(4): 877-882 (1995).
Fan, et al. “Antigen conformation dependence of chlamydia trachomatis infectivity neutralization”, The Journal of Infectious Diseases vol. 176: 713-721 (1997).
Filip, et al. “Solubilization of the cytoplasmic membrane of escherichia coli by the ionic detergent sodium-lauryl sarcosinate”, Journal of Bacteriology vol. 115(3): 717-722 (1973).
Iliffe-Lee, et al. “Regulation of carbon metabolism in chlamydia trachomatis”, Molecular Microbiology vol. 38(1): 20-20 (2000).
Ivens, et al. “A physical map of the Leishmania major Friedlin genome”, Genome Research vol. 8(2): 135-145 (1998).
Kalman, et al. “Comparative genomes of chlamydia pneumoniae and chlamydia trachomatis”, Nature Genetics vol. 21: 385-389 (1999).
Kubo, et al. “Characterization and functional analysis of PorB, a chlamydia porin and neutralizing target”, Molecular Microbiology vol. 38(4): 772-780 (2000).
Moulder, et al. “Interaction of chlamydiae and host cells in vitro”, Microbiological Reviews vol. 55(1): 143-190 (1991).
Newhall, et al. “Biosynthesis and disulfide cross-linking of outer membrane components during the growth cycle of chlamydia trachomatis”, Infection and Immunity vol. 55(1): 162-168 (1987).
Read, et al. “Genome sequences of chlamydia trachomatis MoPn and chlamydia pneumoniae AR39”, Nucleic Acids Research vol. 28(6): 1397-1406 (2000).
Sanchez-Campillo, et al. “Identification of immunoreactive proteins of chlamydia trachomatis by western blot analysis of a two-dimensional electrophoresis map with patient sera”, Electrophoresis vol. 20:2269-2279 (1999).
Sardinia, et al. “Developmental regulation of the cysteine-rich outer-membrane proteins of murine chlamydia trachomatis”, Journal of General Microbiology vol. 134: 997-1004 (1988).
Stephens, et al. “High-resolution mapping of serovar-specific and common antigenic determinants of the major outer membrane protein of chlamydia trachomatis”, J. Exp. Med. vol. 167:817-831 (1988).
Stephens, et al. “Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis”, Science vol. 282: 754-759 (1998).
Stephens, et al. “Antigen Variation of Chlamydia trachomatis”, In J.W. Moulder (ed.), Intracellular Parasitism, CRC Press, Boca Raton, pp. 51-62.
Su, et al. “Protective efficacy of a parentally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of chlamydia trachomatis genital tract infection: Sertum neutralizing IgG antibodies do not protect against chlamydial genital tract infection”, Vaccine vol. 13(11): 1023-1032 (1995).
Thylefors, et al. “Global data on blindness”, Bulletin of World Health Organization vol. 73(1): 115-121 (1995).
Tuffrey, et al. “Heterotrophic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein”, Journal of Gen Microbiology vol. 138: 1707-1715 (1992).
Wyllie, et al. “The major outer membrane protein of chlamydia psittaci functions as a porin-like ion channel”, Infection and Immunity vol. 66(11): 5202-5207 (1998).
GenBank Accession No. AAC68308 published Oct. 30, 2000.
GenBank Accession No. AE001342 AE001273, deposited Oct. 30, 2000.
GenBank Accession No. H71479 published Oct. 8, 1999.
GenBank Accession No. NP_225049 published Sep. 10, 2001.
GenBank Accession No. CAC44728 published Jul. 25, 2001.
GenBank Accession No. H81742 published May 11, 2000.
GenBank Accession No. AAF38966 published May 26, 2000.
GenBank Accession No. NP_220232 published Sep. 10, 2001.
GenBank Accession No. P38006 published Aug. 20, 2001.
GenBank Accession No. NP_296470 published Oct. 2, 2001.
GenBank Accession No. Q9PLL3 published Oct. 16, 2001.
Kubo Aya
Stephens Richard
Baba Edward
Bozicevic Field & Francis LLP
Francis Carol L.
Shahnan-Shah Khatol S
Swartz Rodney P
LandOfFree
Porin B (PorB) as a therapeutic target for prevention and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Porin B (PorB) as a therapeutic target for prevention and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Porin B (PorB) as a therapeutic target for prevention and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3461925